Sugi Predict

Sugi Predict / Compounds / SCHEMBL1623079

SCHEMBL1623079

SCHEMBL1623079

COC(=O)c1ccc2cc(B3OC(C)(C)C(C)(C)O3)ccc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTPN11 Q06124 1/20 0.47
▸ CYP19A1 P11511 1/20 0.45
▸ CYP11B1 P15538 1/20 0.45
▸ CYP11B2 P19099 1/20 0.45
▸ HDAC1 Q13547 1/20 0.45
▸ LPL P06858 1/20 0.44
▸ LIPG Q9Y5X9 1/20 0.44
▸ LCK P06239 1/20 0.44
▸ HIF1A Q16665 3/20 0.43
▸ CA1 P00915 5/20 0.41
▸ CA2 P00918 5/20 0.41
▸ CA9 Q16790 4/20 0.41
▸ CA12 O43570 1/20 0.41
▸ CA7 P43166 1/20 0.41
▸ XDH P47989 1/20 0.41
▸ CA14 Q9ULX7 1/20 0.41
▸ ALOX15 P16050 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ HGFAC Q04756 1/20 0.40
▸ PLAU P00749 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29750908 1.00 PTPN11 (0.47) PTPN11CYP19A1CYP11B1CYP11B2HDAC1
SCHEMBL31162850 0.96 HDAC1 (0.44) PTPN11CYP19A1CYP11B1CYP11B2HDAC1
SCHEMBL15774244 0.96 HDAC1 (0.44) PTPN11CYP19A1CYP11B1CYP11B2HDAC1
SCHEMBL15897022 0.89 LIPG (0.57) CYP19A1CYP11B1CYP11B2LPLLIPG
SCHEMBL28507918 0.85 AAK1 (0.43) LPLLIPGHIF1ACA1CA2
SCHEMBL105161 0.85 CA1 (0.50) LPLLIPGCA1CA2CA9
SCHEMBL17749163 0.84 LIPG (0.48) LPLLIPGCA1CA2CA9
SCHEMBL29535925 0.82 LOXL2 (0.45) LPLLIPGHIF1ACA1CA2
SCHEMBL1902494 0.82 LOXL2 (0.45) LPLLIPGHIF1ACA1CA2
SCHEMBL23262307 0.82 HTT (0.50) CYP19A1CYP11B1CYP11B2LCKALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4257191-A2 HETEROCYCLIC PROLINAMIDE DERIVATIVES Orion Ophthalmology LLC (US) 2023-10-11 — — EP disclosed
EP-3472149-B1 HETEROCYCLIC PROLINAMIDE DERIVATIVES Orion Ophthalmology LLC (US) 2023-08-30 — — EP disclosed
CN-107567443-B Biaryl derivatives as GPR120 agonists 株式会社LG化学 2023-04-28 — — CN disclosed
CN-115925679-A Biaryl derivatives as GPR120 agonists 株式会社LG化学 2023-04-07 — — CN disclosed
EP-3239143-B1 BIARYL DERIVATIVE AS GPR120 AGONIST LG CHEMICAL LTD (KR) 2023-03-22 — — EP disclosed
CN-110114338-B Retinoid derivatives having antitumor activity 比奥吉公司 2022-10-21 — — CN disclosed
US-20220267306-A1 HETEROCYCLIC PROLINAMIDE DERIVATIVES Orion Ophthalmology LLC (US) 2022-08-25 — — US disclosed
US-11377439-B2 Heterocyclic prolinamide derivatives Orion Ophthalmology LLC (US) 2022-07-05 — — US disclosed
CN-114685453-A Heterocyclic prolinamide derivatives 奥瑞恩眼科有限责任公司 2022-07-01 — — CN disclosed
US-20220135574-A1 BIARYL DERIVATIVE AS GPR120 AGONIST LG CHEM, LTD. (KR) 2022-05-05 — — US disclosed
WO-2016075224-A1 6-AMINO-7-BICYCLO-7-DEAZA-PURINE DERIVATIVES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2016-05-19 — — WO disclosed
WO-2013025733-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS INTERMUNE, INC. (US) 2013-02-21 — — WO disclosed
US-7928264-B2 Aminoalcohol derivatives ASTELLAS PHARMA INC. (JP) 2011-04-19 — — US disclosed
EP-1791811-B1 AMINOALCOHOL DERIVATIVES ASTELLAS PHARMA INC (JP) 2009-12-23 — — EP disclosed
US-20080039506-A1 Aminoalcohol Derivatives ASTELLAS PHARMA INC. (JP) 2008-02-14 — — US disclosed
EP-1791811-A1 AMINOALCOHOL DERIVATIVES Astellas Pharma Inc. (JP) 2007-06-06 — — EP disclosed
WO-2006033446-A1 AMINOALCOHOL DERIVATIVES ASTELLAS PHARMA INC. (JP) 2006-03-30 — — WO disclosed
EP-1572693-A1 MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITING COMPOUNDS Pharmacia Corporation (US) 2005-09-14 — — EP disclosed
US-20040209897-A1 Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds PHARMACIA CORPORATION 2004-10-21 — — US disclosed
WO-2004058762-A1 MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITING COMPOUNDS PHARMACIA CORPORATION (US) 2004-07-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220135574-A1 BIARYL DERIVATIVE AS GPR120 AGONIST GPR119, GLP1R, GIPR PTPN11 3451/4885CYP19A1 572/4885CYP11B1 226/4885
US-20040209897-A1 Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds MAPKAPK2, MAP3K2, MKNK2 PTPN11 938/4885CYP19A1 3527/4885CYP11B1 2021/4885
US-20220267306-A1 HETEROCYCLIC PROLINAMIDE DERIVATIVES HTRA1, ALDH1A2, HTRA2 PTPN11 2369/4885CYP19A1 567/4885CYP11B1 844/4885
US-11377439-B2 Heterocyclic prolinamide derivatives HTRA1, ALDH1A2, HTRA2 PTPN11 2494/4885CYP19A1 454/4885CYP11B1 697/4885
US-20080039506-A1 Aminoalcohol Derivatives HRH4, HRH2, CBR3 PTPN11 3832/4885CYP19A1 2340/4885CYP11B1 502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.